Company news
Celcuity Inc. news in 2021
Celcuity Inc.'s news releases, calls and decks from 2021, newest first.
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
December 9, 2021
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
December 1, 2021
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
November 28, 2021
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
November 14, 2021
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
November 8, 2021
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 7, 2021
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
October 28, 2021
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
October 17, 2021
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 8, 2021
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 4, 2021
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
August 1, 2021
Celcuity to Participate in the William Blair Biotech Focus Conference
July 7, 2021
Celcuity Announces Pricing of Follow-on Offering
June 27, 2021
Celcuity Announces Launch of Follow-on Offering
June 27, 2021
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
June 8, 2021
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 9, 2021
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
April 25, 2021
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
April 11, 2021
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
April 7, 2021
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
April 7, 2021
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
March 15, 2021
Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock
February 28, 2021
Celcuity Prices Upsized Public Offering of Common Stock
February 23, 2021
Celcuity Announces Proposed Public Offering of Common Stock
February 21, 2021
Celcuity Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
February 15, 2021
Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2020 Financial Results and Conference Call
January 31, 2021
Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen
January 26, 2021
Celcuity to Present at the B. Riley Oncology Investor Conference
January 18, 2021
Calls in 2021
Decks in 2021
- Investor Presentation (June 2021)
Investor deck · 37 slides · Jun 28, 2021